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RESUME 
DEVENIR A LONG-TERME DES ENFANTS PREMATURES 
TRAITES PAR 
VENTILATION EN PRESSION POSITIVE CONTINUE 
La ventilation en pression positive continue (Continuous Positive Airway Pressure, CPAP), 
utilisée pour la première fois chez les prématurés en 1971, est une technique 
actuellement très largement utilisée dans les unités néonatales. L'utilisation de la CPAP 
présente de nombreux avantages à court terme: diminution de la fraction maximale 
inspirée d'oxygène, de la durée de l'oxygénothérapie, du· taux d'intubation et donc du 
recours à une ventilation mécanique, réduction de l'utilisation des amines, des curares et 
de la morphine, possible prévention de l'apparition d'une bronchodysplasie pulmonaire, et 
possibles réductions du nombre d'infections postnatales et des entérocolites nécrosantes. 
Mais peu d'études existent concernant les effets à long terme de la CPAP sur le 
neurodéveloppement et la croissance, qui constituent l'objectif de la présente étude. 
L'utilisation systématique de la CPAP comme alternative à la ventilation mécanique a été 
introduite à Lausanne en 1998. La population cible de cette étude est constituée des 
prématurés nés à moins de 32 semaines de gestation ou pesant moins de 1500 g à la 
naissance; ils ont été systématiquement suivis jusqu'en âge préscolaire dans le cadre de 
l'étude de cohorte «Unité de Développement, CHUV». L'originalité de ce travail réside 
dans le fait d'évaluer le neurodéveloppement et la croissance à long terme d'enfants 
prématurés traités préférentiellement avec la CPAP, en comparaison avec un groupe 
historique contrôle traité par d'autres modes ventilatoires, en tenant compte de nombreux 
autres paramètres néonataux. 
Du point de vue du neurodéveloppement, l'usage de la CPAP montre une tendance à 
diminuer l'incidence d'hémorragie intraventriculaire et le risque d'avoir un mauvais 
neurodéveloppement à 6 mois. Ces résultats positifs sur le neurodéveloppement 
s'estompent à l'âge de 18 mois, où persiste néanmoins une valeur plus élevée du quotient 
de développement, et disparaissent complètement en âge préscolaire. 
Du point de vue de la croissance, l'utilisation de la CPAP ne montre aucun effet sur le 
poids, mais par contre un effet positif sur la taille à 6 et 18 mois et sur le périmètre crânien 
à 6 mois, 18 mois et en âge préscolaire. 
Malgré le caractère non randomisé de cette étude, les résultats positifs obtenus ici 
permettent sans conteste de s'assurer d'une utilisation de la CPAP sans effet négatif sur 
le neurodéveloppement et la croissance, et fournissent donc un argument supplémentaire 
pour l'utilisation systématique de la CPAP chez les prématurés. 
A ma famille 
Je remercie: 
Mon directeur de thèse, 
le Professeur Adrien C. Moessinger, 
pour m'avoir soutenu activement dans ce travail 
et dans le reste de ma carrière, 
pour m'avoir fait partager son expérience de la néonatalogie, 
pour avoir su par moment ajuster mon enthousiasme, 
sans jamais balayer mes rêves, 
pour tous ses précieux conseils, 
pour avoir toujours tenu parole, 
pour m'avoir fait confiance 
le Docteur Jean-François Toisa, 
pour son enthousiasme, ses qualités d'enseignant, 
ses conseils précieux, son œil critique 
et son sens de l'humour 
Monsieur Guy Van Melle, 
pour son écoute attentive, 
et pour toutes les heures passées à faire des calculs 
avec toujours la même patience et sympathie 
Madame Margarita Forcada-Guex, 
pour sa collaboration fructueuse 
Eur J Pediatr (2007) 166:473--483 
DOI 10.1007/s0043 l-006-0272-3 
\ 
Long-term outcome of ·preterm infants treated with nasal 
continuous positive airway pressure 
Pia Wintermark •Jean-François Toisa• 
Guy Van Melle •Margarita Forcada-Guex • 
Adrien C. Moessinger 
Received: 21 April 2006 / Revised: 14 July 2006 / Accepted: 15 July 2006 / Published online: I 7 October 2006 
(Ç1 Springer-Verlag 2006 
Abstract This study's aim was to assess neurodevelop-
mental and growth outcome until the age of 4 years of 
premature infants placed on early nCPAP, in the setting of 
the neonatal intensive care unit (NICU) and follow-up 
program of the Division of Neonatology of the Department 
of Pediatrics of the University Hospital, Lausanne, Switzer-
Jand. Ail consecutive inborn infants weighing <1500 g or 
<32 "':'eeks of gestational age admitted to the NICU during 
two perîods of 12 months-7 .1996-6.1997 and 7.1998-
6.1999-were compared before and after the systematic 
application of early nCPAP. Of 172 infants admitted to the 
NICU, 150 (87%) survived. 126 (84%) were tested at 6 
months' corrected age, 121 (81%) at 18 months' corrected 
age, and 117 (78%) at the age of 4 years. Detailed perinatal 
data were collected. Follow-up included neurological 
examination, developmental testing and measurement of 
growth parameters. Statistical analyses were performed. 
Early application of nCPAP and avoidance of mechanical 
ventilation showed no adverse effects on neurodevelopment 
and growth. A significantly higher developmental quotient 
was found in the nCPAP group at 18 months' corrected age. 
Severa! trends were also noted in the nCPAP group with a 
decrease of intraventricular hemorrhage and in "abnormal 
neurodevelopmènt" at 6 months corrected age, a biggcr 
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head circumference at ail different tested ages and a greater 
height at 6 and 18 months corrected ages. In conclusion, 
our study of developmental outcome documents the 
absence of any harmful effect of early application of 
nCPAP to treat respiratory failure in very Jow birthweight 
infants. 
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Abbreviations 
nCPAP nasal continuous positive aiiway pressure 
VLBW very low birth weight 
DQ developmental quotient 
GII general intellectual index 
NBRS neurobiological risk score 
IVH intraventrîcular hemorrhage 
PVL periventrîctilar leukomalacia 
ROP retinopathy of prematurîty 
AER audito1y evoked responses 
DQ developmental quotient 
GII general intellectual index 
Introduction 
Early nasal continuous positive airway pressure (nCPAP) 
use for premah1re infants with respiratory distress of 
vmious origins has recently been widely introduced in 
neonatal intensive care. It has been shown to lower the 
intubation rate and shorten 0 2 therapy without altering 
neonatal mortality and morbidity [ 1, 7, 14, 21, 28]. A 
decreased incidence of bronchopulmonary dysplasia has 
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diagnosis of clinical chorioamnionitis included a patholog-
ical placenta or at least two of the following conditions (or 
only one if associated with an antibiotic treatment): 
maternai temperature >38°C on two occasions, maternai 
CRP >20 mg/L, maternai leukocytosis (>20x 109 IL white 
blood cells), or positive bacterial culture of amniotic fluid 
obtained by amniocentesis. Duration of the different types 
of respiratory support (nCPAP, mechanical ventilation, 
oxyhood, and high-frequency oscillatory ventilation) was 
precisely collected. Intubation rate and incidence of 
pneumothorax were noted. Chranic Jung disease was 
considered if infants had either supplemental 0 2 require-
ments ~28 days, or beyond 36 weeks [3, 35]. Therapies 
including sedation and pressor support were compared 
between the graups. 
Short-term outcome included results of ultrasonographie 
examination of the brain [ 10, 29], retinopathy of prematu-
rity (ROP) screening [6] and auditory evoked responses 
(AER) [30]. Infants were evaluated at follow-up with a 
medical history, a physical examination, a standard neuro-
Jogical examination and developmental testing. Develop-
ment was tested rautinely by using at 6 and 18 months of 
corrected age the Griffiths' Developmental Scales with 
calculation of a "developmental quotient" (DQ) [ 15], and 
mean and standard-deviations were those defined in the 
revised version of the Griffiths scales [20]. At the age of 4 
years the McCarthy developmental scales with calculation 
of a "general intellectual index" (GII) [27] was used. 
Certified testers who performed the neurological . and 
developmental examinations were not implicated in the 
analyses of this study. Major impairments included con-
ditions that almost inevitably had a major effect on the 
child's life such as cerebral palsy, severe visual impairment, 
neurosensory heming Joss, mental retardation, epilepsy and 
severe psychological disorder, as defined by Fawer et al. 
[13]. Neurapsychological anomalies involved Jess severe 
organic conditions including neuramotor signs, minor 
visual impairment, minor hearing Joss, language disorder 
and behavior disorder, as defined by Fawer. et al. [13]. 
Patients were classified as "normal" if their develôpmental 
testing scores were Jess than one standard-deviation below 
average, as "mild retardation" if scores were between one 
and two standard-deviations below average, and as "severe 
retardation" if scores were more than two standard-devia-
tions below average [15, 20, 27]. Patients were classified as 
having an "abnormal neurodevelopment" if they had at 
least one minor neurological abnormality or if their 
developmental testing scores were more than one stan-
dard-deviatiori below average. Weight, height and head 
circumforence measured at the different testing ages were 
expressed in percentiles de1ived by relating the measures to 
the infants' corrected age, according to the Swiss national 
growth curves [22]. 
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Differences in neonatal data and neurodevelopmental 
outcome between the graups were assessed in an univariate 
appraach by the nonparametric Wilcoxon rank-sum (Mann-
Whitney) test for continuous values or Fisher's exact test. 
for categorical data. 
For research questions (related to the effects of nCPAP) 
the p value was set at 0.001 applying a Bonferroni 
correction for the 50 tests that were performed. 
I.n order to contrai the plausible effects of the neonatal 
variables that were statistically different between the two 
groups on outcome, and to detennine the exact influence of 
nCPAP, ail comparisons at the different ages were adjusted 
for these variables. Baseline comparisons . of the two 
treatment groups was set at p<0.01 to determine the 
neonatal variables for which an adjustment was warranted 
in later comparisons. The level of 0.01 was chosen to be 
sure to include ail variables that might be different between 
the two graups and then have a plausible impact. 
Furthennore, in order to control the effects of gestational 
age and intrauterine growth retardation, considered impor-
tant detenninants of outcome, we performed a complemen-
tary analysis. Using children in the two groups who were 
tested at the different ages, a matched pair analysis was 
performed using gestational age (±2 days) and small for 
gestational age status as matching criteria, choosing 
(arbitrarily) the first born match when several were 
available. 
Ali calculations and tests were performed using the 
statistical software package Stata, Release 8.2 (Stata Corp., 
College Station, TX). 
Results 
The main neonatal characteristics of our population are 
described in Table 1. The two graups were comparable 
regarding most perinatal and neonatal data, except gesta-
tional age, clinical infection, thrambocytopenia, hypomag-
nesaemia, chorioamnionitis and hypothermia. Of note, there 
was no statistical difference in birth weight, sex distribu-
tion, socio-economic status, or total hospital stay. There 
was also no statistical difference in neurobiological risk 
score. The survival rate in infants weighing <1500 g or 
bom at <32 weeks gestational age was 88% (n==82) in the 
contrai group and 86% (11==68) in the nCPAP group. The 
mortality rates of the contrai group and the nCPAP group 
were 12% (11/93) and 14% (11/79), respectively, and were 
not statistically different. This is in general accordance with 
what has been previously described in the literature [26], 
describing a mean mortality rate in VLBW of 8% with a 
range between 3 and 14%. Among the twenty-two deceased 
patients {13%), 7 <lied during the first day (extreme 
prematurity, one in the contrai graup and six in the nCPAP 
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Table 2 includes the short-term outcome measurements 
(intraventricular hemorrhage, periventricular. Ieukomalacia, 
retinopathy of prematurity, and auditory evoked responses) 
and compares the findings of both groups including either 
the entire group or the findings restricted to survivors 
included in the long-term follow-up. There was no 
statistical difference between the two groups on the 
incidence of intraventticular hemorrhage and periventricu-
lar leukomalacia. Numbers of retinopathy of prematurity 
stages 3 or above and abnormal auditory. evoked response 
were similar between the two groups. 
Tables 3, 4 and 5 present the results of the neuro-
developmental examination at 6 months, 18 months, and at 
4 years of age, respectively. The only significant difference 
Table 2 Short-tenn outcome 
Contrai nCPAP 
group group 
ail patients, ail patients, 
n=93 n=79 
Intraventricular hemorrhage (IVH) 
Number of examined infants n=88 n=78 
Grades t [n (%)] 
Grade 0 64 (72.7) 60 (76.9) 
Grade 1 7 (8.0) 9 (11.5) 
Grade 2 9 (10.2) 3 (3.9) 
Grade 3 2 (2.3) 3 (3.9) 
Grade 4 6 (6.8) 3 (3.9) 
Periventricular leukomalacia (PVL) 
Number of examined infants n=88 n=78 
Grades t [11 (%)] 
Grade 0 76 (86.4) 68 (87.2) 
Grade 1 8 (9.1) 9 (11.5) 
Grade 2 0 (0.0) 0 (0.0) 
Grade 3 3 (3.4) 1 (1.3) 
Grade 4 . 1 (1.1) 0 (0.0) 
Retinopathy of prematurity (ROP) 
Number of examined infants n=67 n=61 
Stages § [11 (%)] 
Stage 3 or above 2 (3.0) 1 (1.6) 
Auditory evoked responses (AER) 
Number of examined infants 11=43 n=41 
Classification Il [11 (%)] 
0 =normal 29 (67.4) 30 (73.2) 
1 = firstrecording abnonnal 6 (! 4.0) 11 (26.8) 
(second recording normal) 
2 = second recording abnonna l 3 (7 .0) 0 (0.0) 
(first recording nonnal) 
3 = first and second recordings abnonnal 5(11.6) 0 (0.0) 
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was a higher mean developmental quotient restricted to the 
18 month examination in the patient group with preferential 
use of nCPAP (p=0.0002). The two modes of ventilatory 
approach had no statistical influence on the other neuro-
developmental data. 
Figure l presents the evolution of growth parameters at 
the different ages. The only significant difference was a 
taller height equally restricted to the 18-month examination 
in the nCPAP group (p=0.001). The other comparisons did 
not show any statistical difference. 
Perinatal variables that were statistically different be-
tween the two groups were gestational age, clinical 
infection, thrombocytopenia, hypomagnesaemia, chorioam-
nionitis and hypothermia, as detailed in Table 1. Because 
p* (adjusted p) Control nCPAP p* ( adjusted p) Matched 
group group pair 
survivors survivors analysis 
p* 
n=78 11=68 
0.4 (0.03) 0.2 (0.09) 0.1 
6 J (78.2) 56 (82.4) 
6 (7.7) 9 (13.2) 
9 (! 1.5) 2 (2.9) 
1 (1.3) l ( 1.5) 
1 (! .3) 0 (0.0) 
11=78 11=68 
0.8 (0.8) 0.8 (0.7) 0.7 
67 (85.9) 60 (88.2) 
7 (9.0) 7 (10.3) 
0 (0.0) 0 (0.0) 
3 (3.9) 1 (1.5) 
1 (1.3) 0 (0.0) 
n=67 11=60 
1.0 1.0 
2 (3.0) 1 (1.7) 
11=43 11=40 
0.02 (0.8) 0.02 (0.9) 0.03 
29 (67.4) 30 (75.0) 
6 (14.0) 10 (25.0) 
3 (7.0) 0 (0.0) 
5 (11.6) 0 (0.0) 
* For research questions relating to the effects of nCPAP, p (and adjusted p)<0.00 l was used to determine significant effects. Adjusted 
p represented the p values of analyses performed again after adjusting for the variables that were statistically different between the 
two groups 
t Classification of PVL, according to de Vries et al. [ 10) 
§ Classification of ROP, according to the International Committee for the Classification of the late Stages of Retinopathy of Prcmaturity [6] 
Il Classification of AER, according to Pasman et al. [30] 
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Table 5 Neurodevelopmental outcome at age of 4 years 
Control nCPAP p* (adjusted p) Matched pair 
group, n=57t group, n=60 t analysis, p* 
Age at testing, months [mean±SD] 48.9±5.4 47.2±3.3 0.04 
Neurodevelopmehtal outcome 
General intellectual index (GU) t 
General intellectual index (GII) [mean±SD] 101.6±17.1 99.7±17.7 0.2 (0.6) 0.8 
Ranges 0.4 ( 1.0) 1.0 
1 = normal=>84 [n (%)] 46 (80.7) 47 (78.3) 
2 = mild retardation=68-84 [n (%)] 8 (14.0) 12 (20.0) 
3 = severe retardation=<68 [n (%)] 3 (5.3) 1 ( 1. 7) 
Neurological status 0.08 (0.7) 0.6 
0 =normal [n (%)] 23 (40.4) 26 (43.3) 
1 = 1 neuropsychological anomaly [11 (%)] 21 (36.8) 24 (40.0) 
2 = >I neuropsychological anoma.lies [n (%)] 8 (14.0) 7 (11.7) 
3 = 1 major impainnent [11 (%)] 0 (0.0) 3 (5.0) 
4 = 1 major impainnent + ~I neuropsychological anomalies [11 (%)] 5 (8.8) 0 (0.0) 
5 = >I major impainnents [n .(%)] 0 (0.0) 0 (0.0) 
6 = ~I major impairments + ~ 1 neuropsychological anomalies [n (%)] 0 (0.0). 0 (0.0) 
"Abnomrnl neurodevelopment" t 34 (59.7) 36 (60.0) 1.0 (0.9) 0.5 
* For research questions relating to the effects of nCPAP, p (and adjusted p)<0.001 was used to determine significant effects. Adjusted p represented 
the p values of analyses perfonned again after adjusting for the variables that were statistically different between the two groups 
t General lntellectual Index was calculated using the McCarthy's developmental scales [27) 
t An "abnormal neurodevelopment" was defined by a general intellcctual index more than 1 standard-deviation below average (less than 84) [27] 
or a pathological neurological status 
these significant va1iables might have a plausible relationship 
to neurological and growth outcomes, analyses were per-
formed again after adjusting for these variables and the results 
wcre similar. Mean developmental quotient at 18 months 
examination in the patient group with preferential use of 
nCPAP remained higher (p=0.006). Height was taller at 18. 
months of corrected age, but the difference was not 
statistically significant (p=0.11 ). Of note, after adjusting for 
the variables mentioned above, infants with preferential use 
of nCPAP tended to have a Jess ,severe grade of intraven-
tricular hemorrhage (p=0.027) with a risk divided by two; 
however, this finding did not reach statistical significance. In 
the same way, head circumference tended to be bigger in 
infants with preferential use of nCPAP at the different tested 
ages, but this did not reach statistical significance (respec-
tively, p=0.039 at 6 months of comcted age, p=0.030 at 18 
months of corrected age, and p=0.12 at the age of 4 years). 
Smaller mean gestational age was observed in the 
nCPAP group (28.8 weeks versus 30.1 weeks for the 
control group, p=0.0007), and intrauterine growth retarda-
tion (weight at birth <l Oth percentile for gestation al age) 
tended to be more frequent in the control group (39% 
versus 23% in the nCPAP group, p=0.033). Considering 
that these factors are important determinants of outcome we 
performed an additional paired comparison, as outlined in 
the methods section. Thirty-eight pairs of children were 
thus fom1ed and the results reinforced the trends noted in 
the prcvious analyses. The value of DQ at 18 months was 
significantly higher in the nCPAP group (p<0.0001). Height 
was sigf!iticantly taller in the nCPAP group at 6 months 
(p<0.0005) and at 18 mohths (p<0.0001). A trend towards a 
diminution in the incidence of intracranial hemorrhage in 
the nCPAP group was noted (p=O. l, with a risk divided by 
two, which may be clinically relevant). Head circumference 
was larger and significantly so at ail three postnatal ages in 
the group with preferential use of nCPAP (p<0.001 at 6 
months, p<O .008 at 18 months and p<O .009 at the age of 4 
years). 
Discussion 
The management of respirat01y distress in premature 
newborn infants using preferentially early nasal nCPAP 
rather than conventional ventilation has gained wider 
acceptance over the last decade. It has been shown to 
decrease respiratmy morbidity [2, 7-9, 11, 14, 21, 28]. Its 
influence on other neonataloutcome [7, 11, 12] is debated. 
Controlled data on long-term neurodevelopmental outcome 
and somatic growth are not yet available. 
The results of our study confirrn the favorable influence 
of nCPAP on early neonatal outcome measurements, and 
document the safety of this approach in tenns of long-terrn 
neurodevelopmental outcome and somatic growth. Indeed, . 
follow-up data up to 4 years of age of newborn infants 
<1500 g and/or <32 weeks gestation treated either with 
~ Sprlnger 
Eur J Pediatr (2007) 166:473-483 
ductus arteriosus was not different. These combined 
findings could suggest a favorable influence of nCPAP on 
cerebral hemodynamics. This could happen via a mecha-
nism including reduced intrathoracic pressure swings and 
more physiological venous retum and cardiac output, the 
disturbances of which have been implicated as a possible 
mechcmism for intracranial bleeding [7]. In contrast, the 
incidence of periventricular leukomalacia was unchanged 
(adjusted p=0.84). Of note, the incidence of chorioamni-
onitis, a known risk factor of periventricular Ieukomalacia, 
tended to be more frequent in the nCPAP group, and might 
then have blurred some positive effects of nCPAP on the 
incidence of periventricular leukomalacia. However this 
item was included in the variables that were statistically 
different between the two groups and the incidence of 
periventricular Ieukomalacia was not different between the 
two groups in the analyses after adjusting for these 
variables. Moreover, physiopathological mechanisms un-
derlying periventricular leukomalacia seemed to be differ-
ent from th ose of intracranial hemorrhage, and · might 
therefore be Jess subject to the mode of ventilatory support. 
It is important to note that al! infants diagnosed with 
IVH 3-4, PVL 2-4 or ROP 3-4 received mechanical 
ventilation during the first week of life (duration between 
one day and more than one week). 
With regards to long-tenn outcome, the use of nCPAP 
appears to diminish the risk of having an abnormal 
neurodevelopment at 6 months of age (22% versus 39% 
in the contrai group, adjusted p=0.093) and to diminish as 
well the risk of having a DQ (developmental quotient) 
below one standard deviation at 6 months (2% versus 8% iil 
the control. group, adjusted p=0.12). This effect on the DQ 
seems to decrease with advancing age but is still significant 
at 18 months with values of 110.6 versus 104.8 after 
adjustment (p=0.006), and disappears at the age of 4 years. 
Sorne of the neonatal effects of nCPAP on neurodevelop-
ment might be bJurred with advancing age (intervening 
diseases, rehospitalization rate, stimulating environment, 
resort to special education resources), explaining why there 
is no more difference at the age of 4 years. 
When considering somatic growth, nCPAP use was not 
associated with any difference in weight whereas height 
tended to be tal.ler at 6 months (p=0.04, adjusted p=0.084) 
and at 18 months as well (p=0.001, adjustedp=0.11). Head 
circumference tended to be larger at 6 months, 18 months 
and at the age of 4 years (respectively, p=0.086/adjusted 
p=0.039 at 6 months corrected age; p=0.24/adjusted 
p=0.030 at 18 months of corrected age; and p=0.031 
adjusted p=0.12 at age of 4 years). Considering the link 
between head growth and future cognitive functiori [ 16, 17, 
33], it seems important that this potential effect on head 
circumference be further evaluated since it could be an 
argument in favor of nCPAP use. 
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In this study, we have collected a large number of 
neonatal factors known to potentially influence neur.o-
development and growth. We detennined for each infant 
its NBRS [4]; there was no statistical difference in NBRS 
between the 2 groups, confinning that the infants in both 
groups were comparably sick and equally at risk. Various 
perinatal variables were statistically different between the 
two groups (gestational age, clinical infection, thrombocy-
topenia, hypomagnesaemia, chorioamnionitis and hypother-
mia) and analyses were adjusted for these variables. 
Considering all neonatal factors that were different 
between the two groups, and which motivated the adjust-
ment, it is important to refer to gestational age. Gestation~! 
age was significantly lower in the nCPAP group (28.8 
versus 30.1 weeks gestation in the contrai group, 
p=0.0007), and could bave had a disproportionately 
stronger negative influence on neurodevelopment [ 18, 26]. 
The difference in gestational age between the groups could 
have therefore canceled sorrie positive effects of nCPAP in 
comparison to conventional ventilation. The same consid-
eration was given to the association of fetal growth 
retardation (although not significantly different between 
the groups, p=0.36) [24, 32, 34]. For these reasons we 
performed additional matched pair analyses (matching 
individuals according to their gestational age and the 
presence or absence of fetal growth retardation). The results 
of these pair analyses have to be considered in view of the 
reduction in the number of pairs matched (38 pairs) but can 
be taken to confinn the results of our previous analyses. 
This study describes a fairly recent population of 
consecutively born premature infants who have been 
managed in a modern neonatal ICU environment during a 
relatively short period of time (3 years). The design of the 
study was a retrospective "before-after trial" with a limited 
sample size, and presented the major limitation of not being 
a randomized study. It is important to note that neonatal and 
nenrodevelopmental data were collected separately, in a 
coded and blinded fashion. Ce1iified testers who perfonned 
the neurological and developmental examinations were not 
implicated in the analyses ofthis study, and were blinded to 
the type of rcspiratory support these infants received. 
Another limitation is the difference in follow-up ratio 
between the two study periods, with Jess drop-outs in the 
group with preferential use of nCPAP. However, infants 
who were lost to follow-up did not differ from the studied 
groups conceming their perinatal and neonatal assessment 
and their neurobiological risk score. Of the 33 infants lost 
to follow-up, no information was available for 16 infants 
who moved away from the. test center. Sorne neuro-
developmental information was obtained with a structured 
phone interview or a follow-up in another test center for 17 
infants (12 in the control group and 5 in the nCPAP group). 
In the control group, four children were described as 
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